APPLICATION
ANDA208621
TYPE
ANDA
ORIGINAL APPROVAL
2018-07-02
LATEST ACTION
2023-06-28
ROUTE
ORAL
DOSAGE FORM
TABLET, CHEWABLE
MARKETING STATUS
Prescription
Products
MONTELUKAST SODIUMPrescription
MONTELUKAST SODIUM EQ 4MG BASE · TABLET, CHEWABLE · ORAL
MONTELUKAST SODIUMPrescription
MONTELUKAST SODIUM EQ 5MG BASE · TABLET, CHEWABLE · ORAL
Approval history
2023-06-28Labeling · Supplement 1 · standardAP
2023-06-28Labeling · Supplement 4 · standardAP
2023-06-28Labeling · Supplement 2 · standardAP
2023-06-28Labeling · Supplement 9 · standardAP
2018-07-02UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.